Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. Thank you for joining us for Stereotaxis second quarter 2026 earnings conference call. Certain statements during the conference call and question and answer period to follow may relate to future events, expectations, and as such constitute towards forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or TenQ. We assume no duty to update this statement. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments following the presentation. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Seriotaxis. Please go ahead. Thank you, operator, and good afternoon, everyone. On our last call, we discussed in detail the structural transformations taking place at stereotaxis. We had just celebrated a particularly milestone-rich period with regulatory approvals for a new robot, both therapeutic and diagnostic catheters, and a digital surgery system. These products individually and collectively as a synergistic ecosystem, create an attractive foundation for us to scale commercialization with reduced barriers to adoption and a much more attractive business model. During the second quarter, Stereotexis reached an important commercial inflection point as o...